Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

NCT03465540 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic decisions

Conditions

Multiple Myeloma
Acute Myeloid Leukemia
Non-Hodgkins Lymphoma
Myelodysplastic Syndrome
AML
MDS
NHL

Interventions

DRUG: AMG 397
DRUG: Dexamethasone
DRUG: Azacitidine

Sponsor

Amgen